Polycythemia Vera
Show Only Open Trials
1.
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
- Study Status: Open to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
- Protocol ID: MPD-RC 111
2.
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)
- Study Status: Open to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Polycythemia Vera (PV)
3.
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
- Study Status: Open to Enrollment
- Sponsor: Incyte Corporation
- Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
4.
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
- Study Status: Closed to Enrollment
- Sponsor: Myeloproliferative Disorders-Research Consortium
- Disease Status and/or Stage: Polycythemia Vera (PV)
